Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTMO9HF)

• DTT Name: Advanced glycosylation end product receptor (AGER) DTT Info
• Gene Name: AGER

Molecule-Related Drug & Molecule List

5 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PF-4494700	DMJ7IKW	Alzheimer disease	8A20	Phase 3	[1]
Pyridoxamine	DMVDCGZ	Diabetic kidney disease	GB61.Z	Phase 3	[2]
Alagebrium chloride	DMD741P	Hypotension	BA20-BA21	Phase 2/3	[3]
TTP-448	DMR37X8	Alzheimer disease	8A20	Phase 2	[1]
TTP-4000	DMCG01R	Alzheimer disease	8A20	Phase 1	[4]

1 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
DBT-066	DMFYCQ1	Dementia	6D80-6D86	Investigative	[5]

References

• [1] Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's disease. Expert Opin Investig Drugs. 2015 Mar;24(3):393-9.
• [2] Pyridoxamine, an inhibitor of advanced glycation end product (AGE) formation ameliorates insulin resistance in obese, type 2 diabetic mice. Protein Pept Lett. 2010 Sep;17(9):1177-81.
• [3] Effect of the age cross-link breaker alagebrium on anterior segment physiology, morphology, and ocular age and rage. Trans Am Ophthalmol Soc. 2009 Dec;107:146-58.
• [4] Receptor for advanced glycation end products: its role in Alzheimer's disease and other neurological diseases. Future Neurol. 2009; 4(2): 167-177.
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2843).